Study of NVL-330 for HER2-altered advanced lung cancer
Part of Cancer clinical trials.
This trial tests a new oral drug called NVL-330 for people with advanced NSCLC whose tumors have a specific change in the HER2 gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has a HER2 change (mutation or amplification)
- Your tumor can be seen on scans (measurable or evaluable disease)
- You have not had major surgery in the last 4 weeks
- You are not currently receiving other cancer treatment or in another clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This trial tests a combination of two drugs, adebrelimab and trastuzumab rezetecan, for people with stage III lung cancer that cannot be removed by surgery and has a specific genetic change called HER2. The goal is to see if this combination shrinks tumors and helps patients live longer.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
Hear when a new Locally Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.